Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ICAM-1 or alphaMbeta2 integral protein in screening of medicine for diagnosing or treating implantation metastatic cancer

A technology of ICAM-1, 1.ICAM-1, applied in the field of biomedicine, can solve the problem of unclear survival mechanism of tumor cell spheroids

Inactive Publication Date: 2017-02-22
广州道瑞医药科技有限公司
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, how freely detached tumor cells survive in the environment of implantation and metastasis and the mechanism of sphere formation at the initial stage of implantation and metastasis are still unclear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ICAM-1 or alphaMbeta2 integral protein in screening of medicine for diagnosing or treating implantation metastatic cancer
  • Application of ICAM-1 or alphaMbeta2 integral protein in screening of medicine for diagnosing or treating implantation metastatic cancer
  • Application of ICAM-1 or alphaMbeta2 integral protein in screening of medicine for diagnosing or treating implantation metastatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0034] 1. Materials and methods

[0035] 1.1 Study Approval

[0036] All animal experiments were performed with institutional approval from the Yale University Animal Care Committee. Human tumor spheroids from patients with advanced (ie, stage III-IV) ovarian cancer were collected from ascitic fluid provided by informed consenting patients as completed at Yale University School of Medicine, New Haven, CT (HIC protocol #1111003959). Clinical paraffin specimens were used after approval by the Ethics Review Committee of Cancer Hospital Affiliated to Harbin Medical University, China.

[0037] 1.2 Animal models

[0038] All animal experiments were performed with the approval of the Yale University Animal Care Committee. All mice were of the C57BL / 6 series. Lysozyme Cre mice were crossed with tomato (mT / mG) mice to extract cells with the lineage marker lysozyme. Nude mice were purchased from Jackson Laboratory. Cell culture medium was grown on 100 μl mouse ovarian cancer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of ICAM-1 or alphaMbeta2 integral protein in screening of medicine for diagnosing or treating implantation metastatic cancer. The application firstly verifies that the ICAM-1 or alphaMbeta2 integral protein plays an important regulating effect in the ovarian cancer implantation metastasis process on a mice in-situ ovarian cancer model and discloses the formation basis mechanism of the ovarian cancer sphere, and can provide theoretical foundation for the screening of the medicine for diagnosing or treating implantation metastatic cancer.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the use of ICAM-1 or αMβ2 integrin in screening medicines for diagnosing or treating implanted metastatic cancer. Background technique [0002] Ovarian cancer (OC) is the second most common cancer and one of the leading causes of death in gynecology in the United States. The high mortality rate is mainly due to the difficulty of diagnosing ovarian cancer in the early stage (I / II) until it spreads to the advanced stage (III / IV). We have reported that the confirmed rates from stage I to IV in OC patients were 7.19%, 8.63%, 72%, and 72.18%, respectively. The prognosis of OC patients is poor, and the five-year average survival rate of OC patients in all stages is 42%. Long-term follow-up of patients with stages III and IV found that the five-year survival rate was less than 10%; however, for patients with early (I-II) diagnosis, especially those whose tumors were con...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K38/18A61K39/395A61P35/04A61K49/00
CPCA61K38/1774A61K38/18A61K39/395A61K49/00
Inventor 王敏
Owner 广州道瑞医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com